Vectura Group Hits GBP9 Million Royalty Target on Glaxo's Ellipta Products
February 16 2017 - 4:07AM
Dow Jones News
By Philip Waller
LONDON--Inhaler developer Vectura Group PLC (VEC.LN) Thursday
said its merger with SkyePharma last year has increased the
company's revenue as it hit a royalty target on a deal with
GlaxoSmithKline PLC (GSK.LN).
Vectura said it achieved the 9 million pounds ($11.2 million)
cap on low single-digit percentage royalties from net sales of
Breo/Relvar Ellipta, Anoro Ellipta and Incruse Ellipta a year
earlier than planned.
The group will record GBP5.4 million of the capped amount-- from
the legacy Skyepharma agreement with GSK--in its 2016 revenues,
representing income since June 10, the effective date of its merger
with Skyepharma.
It comes on top of royalties for a separate Vectura legacy
agreement with GSK, which reached a GBP13 million calendar-year cap
before GSK terminated the deal.
For the financial year to Dec. 31, the group will record GBP7.3
million of royalties under the latter legacy deal.
Chief Executive James Ward-Lilley said: "The merger with
Skyepharma has added to the group's growing revenue."
-Write to Philip Waller at philip.waller@wsj.com
(END) Dow Jones Newswires
February 16, 2017 03:52 ET (08:52 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024